Niagen Bioscience, Inc. — Director's Dealing 2008

Jun 26, 2008

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: ChromaDex Corp. (CDYE(3))
CIK: 0001386570
Period of Report: 2008-06-25

Reporting Person: Dabney Reid J D (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$1.5	2017-12-21	Common Stock (30000)		Direct
Stock Option (right to buy)	$1.5	2018-04-21	Common Stock (50000)		Direct

Footnotes

F1: 6,000 options become exercisable annually beginning on October 4, 2008.

F2: 12,500 options become exercisable on April 21, 2009 and 781 options become exercisable monthly thereafter, except that 782 options become exercisable every fourth month.